HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more.

AbstractBACKGROUND:
Postural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance with an excessive increase in heart rate on standing. beta-Blockade is an appealing treatment approach, but conflicting preliminary reports are conflicting. We tested the hypothesis that propranolol will attenuate the tachycardia and improve symptom burden in patients with POTS. In protocol 1, a low dose (20 mg) was compared with placebo, and the dose response was assessed in protocol 2.
METHODS AND RESULTS:
In protocol 1, patients with POTS (n=54) underwent acute drug trials of propranolol 20 mg orally and placebo, on separate mornings, in a randomized crossover design. Blood pressure, heart rate, and symptoms were assessed while the patients were seated and after standing for up to 10 minutes before and hourly after the study drug. Supine (P<0.001) and standing (P<0.001) heart rates were significantly lower after propranolol compared with placebo. The symptom burden improvement from baseline to 2 hours was greater with propranolol than placebo (median, -4.5 versus 0 arbitrary units; P=0.044). In protocol 2, 18 patients with POTS underwent similar trials of high-dose (80 mg) versus low-dose (20 mg) propranolol. Although the high dose elicited a greater decrease than the low dose in standing heart rate (P<0.001) and orthostatic tachycardia (P<0.001), the improvement in symptoms at 2 hours was greater with low-dose propranolol (-6 versus -2 arbitrary units; P=0.041).
CONCLUSIONS:
Low-dose oral propranolol significantly attenuated tachycardia and improved symptoms in POTS. Higher-dose propranolol did not further improve, and may worsen, symptoms.
AuthorsSatish R Raj, Bonnie K Black, Italo Biaggioni, Sachin Y Paranjape, Maricelle Ramirez, William D Dupont, David Robertson
JournalCirculation (Circulation) Vol. 120 Issue 9 Pg. 725-34 (Sep 01 2009) ISSN: 1524-4539 [Electronic] United States
PMID19687359 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
Chemical References
  • Adrenergic beta-Antagonists
  • Placebos
  • Propranolol
Topics
  • Administration, Oral
  • Adrenergic beta-Antagonists (administration & dosage)
  • Adult
  • Blood Pressure (drug effects)
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Female
  • Heart Rate (drug effects)
  • Humans
  • Male
  • Placebos
  • Postural Orthostatic Tachycardia Syndrome (drug therapy)
  • Propranolol (administration & dosage)
  • Sympathetic Nervous System (drug effects)
  • Tachycardia (drug therapy)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: